GlassScriptPhysician profile
Christian E Berkhahn
NPI 1518005156
$84,517.59
in general payments reported to CMS, 2019-2025
22 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,451 · 2020: $5,672 · 2021: $5,371 · 2022: $932 · 2023: $16K · 2024: $29K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Honoraria: $22K · Travel and Lodging: $6,074 · Food and Beverage: $3,965 · Consulting Fee: $2,940 · Education: $12.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,000.00 |
| Honoraria | $22,100.00 |
| Travel and Lodging | $6,074.14 |
| Food and Beverage | $3,964.74 |
| Consulting Fee | $2,940.00 |
| Education | $12.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $62,036.61 | 2021-2025 | Qelbree, Qelbree |
| Genentech USA, INC. | $10,802.67 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $5,649.29 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $4,233.61 | 2024 | |
| Tris Pharma INC | $648.15 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Merck Sharp & Dohme LLC | $239.96 | 2022-2024 | Vaxneuvance, Rotateq, Gardasil 9 |
| Sanofi Pasteur INC. | $161.39 | 2022-2025 | |
| Corium, LLC | $121.76 | 2023-2025 | Azstarys |
| Neos Therapeutics, LP | $114.88 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $110.20 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $75.08 | 2023-2025 | Doc Band |
| Mckesson Medical-Surgical, INC. | $72.45 | 2023 | |
| Janssen Pharmaceuticals, INC | $60.97 | 2023 | Spravato |
| Adlon Therapeutics L.P. | $41.61 | 2019-2020 | |
| Pfizer INC. | $35.44 | 2019-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $21.96 | 2025 | Dojolvi |
| Verrica Pharmaceuticals INC. | $21.00 | 2024 | Ycanth |
| Glaxosmithkline, LLC. | $17.14 | 2025 | Pediarix, Bexsero, Penmenvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.72 | 2024 | Caplyta |
| Sobi, INC | $13.86 | 2023 | |
| Vertical Pharmaceuticals, LLC | $13.59 | 2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Berkhahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.